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Introduction: Fatigue is a disruptive symptom that inhibits normal functional performance of COPD patients in
daily activities. The availability of a short, simple, reliable and valid scale would improve assessment of the
characteristics and influence of fatigue in COPD.
Methods: At baseline, 2107 COPD patients from the ECLIPSE cohort completed the Functional Assessment of
Chronic Illness Therapy Fatigue (FACIT-F) scale. We used well-structured classic method, the principal components
analysis (PCA) and Rasch analysis for structurally examining the 13-item FACIT-F.
Results: Four items were less able to capture fatigue characteristics in COPD and were deleted. PCA was applied to
the remaining 9 items of the modified FACIT-F and resulted in three interpretable dimensions: i) general (5 items); ii)
functional ability (2 items); and iii) psychosocial fatigue (2 items). The modified FACIT-F had high internal consistency
(Cronbach's α = 0.91) and it did not fit a uni-dimensional Rasch model, confirming the prior output from the PCA. The
correlations between total score and each dimension were ≥ 0.64 and within dimensions ≥0.43 (p < 0.001 for all).
The original and modified FACIT-F had significant convergent validity; its scores were associated with SGRQ total score
(0.69 and 0.7) and mMRC dyspnoea scores (0.48 and 0.47), (p = <0.001 for all). The scale had meaningful discriminating
ability in identifying patients with poor exercise performance and more depressive symptoms.
Conclusion: The original and modified FACIT-F are valid and reliable scales in COPD. The modified version is shorter
and measures not only total fatigue but also its sub-components in COPD.
Keywords: Chronic obstructive pulmonary disease, Fatigue, Exercise capacity, Health statusIntroduction
Fatigue is a disruptive symptom that inhibits normal
functional performance of Chronic Obstructive Pulmonary
Disease (COPD) patients in daily activities [1] and consid-
erably impacts on their quality of life [2]. Fatigue together
with dyspnoea are the most prominent disabling symp-
toms in COPD [3,4]. There is growing interest and atten-
tion on the substantial impact of fatigue on COPD
patients [5,6] and the need of a short, simple, reliable and* Correspondence: alshair02@yahoo.com
1University of Manchester, Medicines Evaluation Unit, NIHR Translational
Research Facility, Manchester Academic Health Sciences Centre, University
Hospital of South Manchester Foundation Trust, Wythenshawe, Manchester, UK
2Hadhramout University of Science and Technology, College of Medicine,
Hadhramout, Yemen
Full list of author information is available at the end of the article
© 2012 Al-shair et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orvalid instrument that can improve the assessment of fa-
tigue in COPD.
The Functional Assessment of Chronic Illness
Therapy-Fatigue scale (FACIT-F scale) is a 13-item
scale [7,8] that was previously employed in cohorts of
patients with COPD [5]. However; no study examined its
psychometric properties, validity and reliability in this
population. Using a well-structured classic framework as-
sessment, principal component analysis (PCA) and Rasch
analysis, we examined the psychometric properties of
the scale including its underlying structural construct, valid-
ity of items and possible dimensionality, followed by exam-
ination of its reliability and validity in a large COPD cohort
from the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study [9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modified version for COPD patients.
Methods
The ECLIPSE study (NCT00292552; GlaxoSmithKline
study SCO104960) was an observational prospective
three-year multi-centre study. It was conducted in 46
centres from 12 countries in accordance with the Dec-
laration of Helsinki and good clinical practice guidelines.
A total of 2107 patients were examined at baseline and
completed the FACIT-F questionnaire, of these 1621
patients were followed up for 3 years, and completed the
questionnaire again at the final study visit. Criteria for
enrolment included age between 40–75 years, post-
bronchodilator forced expiratory volume in one second
(FEV1) < 80% of normal predicted, post-bronchodilator
FEV1/forced vital capacity (FVC) ≤ 0.7 and smoking his-
tory ≥ 10 pack-years. At each study visit, patients were
clinically stable for at least 4 weeks before each visit.
Therefore, during the study conduction many visits had
been re-scheduled to meet this criterion. Further details
on this study have been previously published [9,10].
Measurements
The 13-item FACIT-F scale is a self-reported scale,
where subjects respond to each item by choosing one of
five options (Not at all (4 scores), A little bit (3), Some-
what (2), Quite a bit (1), Very much (0) [7,8]. Two items
have to be reversely scored, and overall scores of the
FACIT-F scale range from 0 to 52, with higher scores
signifying less fatigue [7,8]. The scale was originally
developed to assess anemia-related fatigue in patients
with cancer in a 7 days recall period. It had a test-retest
reliability correlation (0.87) and strong internal
consistency (Cronbach’s α coefficient 0.95). It had good
convergent and discrimination validities; e.g., good cor-
relation with the Piper Fatigue scale (0.75) and Profile of
Mood States (0.74), and it differentiated between differ-
ent levels of haemoglobin in patients with cancer [7].
Study patients also completed: St. George’s Respiratory
Questionnaire for COPD patients (SGRQ-C) [11], the
modified Medical Research Council (mMRC) Dyspnea
scale [12], and the Centre for Epidemiologic Studies of
Depression Scale (CES-D) [13]. Lung function tests, and
six minute walk distance (6MWD) [14] were measured.
Statistical analysis
Statistical analyses were conducted in four phases (see
Figure 1):
1) Assessment of traditional psychometric properties:
We used a constructive framework that was based
on previous experiences [2,15-17] to investigate the
presence of:i). Non-applicable items; i.e., items not applicable to
COPD patients’ current life style;
ii). Items showing redundancy of measurement
defined by a high correlation with another item;
iii). Items with a correlation coefficient (r2
coefficient) <0.5 or >0.9 with all the other items;
(r2 coefficient is the value of the squared
correlation between each item and the total score
of all the other items); and
iv). Items with a ‘floor’ or ‘ceiling’ effect (i.e., items
that were mostly answered with “Not at all” or
“Very much”). Importantly, before any item was
removed its clinical importance (content validity)
was considered.2) Principal component analysis (PCA)
An exploratory PCA was performed to examine
loadings of the items for each domain using SPSS
version 15. Kaiser’s criterion of eigen value >1 and
Catell’s scree test were used to determine the number
of components [18]. We conducted both orthogonal
and oblique rotation techniques and found that
oblique (Direct Oblimin) provided the best and easiest
interpretation; nevertheless, an orthogonal approach
(Varimax) provided a very similar result.
The PCA was separately conducted using two
software packages SPSS 15 and Rasch Uni-
dimensional Measurement Model 2030 (RUMM)
[19,20].3) Rasch analysis
Rasch analysis is a sophisticated technique which has
been widely used to assess the psychometric
properties of scales in different fields including
respiratory research [11,20]. It is based on the
assumption that all items measure a single
underlying dimension by examining the fitness and
contribution of each item to measure a single
construct. It also confirms whether a scale meets the
requirements of fundamental measurement, allowing
for mathematical investigation for reasons of misfit
through the assessment of the parametric properties
such as individual person fit and item fit, response
thresholds, differential item functioning (DIF), local
dependency and person separation index (PSI)
[21,22].
Exploratory Rasch analysis was conducted several
times before and after removing items from previous
steps. Taking advantage of the large sample size,
random sampling was used to divide the sample to 4
sub-groups (each >500 patients). This enabled us to
conduct the Rasch analysis in the first group and
validate the results in the other groups. The Rasch
analysis was also performed using the whole sample.
RUMM 2030 (Version 5.1 for Windows, RUMM
Laboratory, Perth, Western Australia) was used [19,20].
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Figure 1 Flow chart illustrating the development of the COPD modified FACT-F scale.
Table 1 Baseline characteristics and demographic of the
study population (data are presented as mean (SD)
unless otherwise noted)
Variable Description
Age (yr) 63.4 (7)
Female (n, %) 732 (35 %)
Current smokers (n, %) 767 (36 %)
Post bronchodilator FEV1 (litres) 1.35 ± (0.52)
Post bronchodilator % predicted FEV1 48 ± (16)
FEV1/FVC (%) 45 ± (12)
GOLD stages II, III, and IV (n, (%)) 925 (44 %), 894 (42 %), 292 (14 %)
BMI (kg/m2) 26.6 ± (5.7)
6MWD (m) 370.1 ± (121.7)
SGRQ (Total score) 49.9 ± (20.1)
mMRC dyspnoea (Median (IQR)) 2 (1 – 2)
CES-D score (Median (IQR)) 9 (4 – 16)
FEV1: Forced expiratory volume in one second; FVC: forced vital capacity; BMI:
body mass index as measured by kilograms over height in meter squared;
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Reliability of the fatigue scale
We investigated the internal consistency of the
original FACIT-F, and the modified version and each
of its dimensions using Cronbach’s α coefficient [23].
A correlation ≥ 0.7 was assumed to indicate that
questions within a dimension are likely to measure
the same construct.
Validity of the fatigue scale
To examine the convergent validity; i.e., the extent
to which the scores of a measure are related to
scores of other constructs [24], the total score of the
original FACIT-F, and the total and dimensional
scores of the 9-item modified FACIT-F were
correlated with impairment in quality of life and the
perception of dyspnoea using SGRQ and mMRC
dyspnoea scales. The discriminating validity was also
examined comparing the mean fatigue scores
between patients with high depressive symptoms and
those with low depressive symptoms (using ≥16
scores cut-off of CES-D), and between patients with
a poor 6MWT performance (less than 350 metres)
or more [25]. Description of additional statistical
analysis can be seen in the Additional file 1
Results
Baseline characteristics and demographic data of the
study patients are shown in Table 1.
1) Assessment of classic psychometric properties:
6MWD: 6 minutes walk distance; mMRC: the modified Medical Research
Council dyspnoea scale; SGRQ: St. George’s Respiratory Questionnaire; CES-D:
The Centre for Epidemiologic Studies Depression scale.Using constructive steps of the classic psychometric
properties assessment, 4 items were unlikely toefficiently assess fatigue in COPD and these were
proposed for deletion as detailed below and in
Additional file 1 Table S1:
“I am too tired to eat”, 1618 patients (76.8%)
responded to this item with “not at all” indicating
lack of applicability in COPD with a low squared
correlation coefficient, (r2 =0.28) and high
floor effect.
Tabl
(load
Item
1 I fe
2 I fe
3 I fe
4 I ha
5 I ha
6 I ha
7 I am
8 I am
9 I ha
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(61.5%) responded to this item with “not at all”. The
mean score has shown moderate high floor effect,
further indicating lack of applicability in
COPD.
“I need to sleep during the day”, we found that 687
patients (32.6%) responded to it with “not at all”
indicating relatively lack of applicability in COPD,
and it also showed a low r2 coefficient, 0.29.
“I feel tired” had a high correlation with 2 other
items (items 1 and 5) indicating redundancy
particularly with item “I feel fatigued”.2) Principal component analysis
The remaining 9 item FACIT-F was subjected to the
PCA. For comparison and to assess advantages of
the previous shortening step, we also ran the PCA
for the whole 13-item scale (Additional file 2). The 9
items of FACIT-F were subjected to the PCA using
SPSS version 15 and RUMM 2030.
The suitability of data for factor analysis was
assessed. Inspection of the correlation matrix
revealed the presence of many coefficient
correlations of 0.3 and above. The Kaiser-Meyer-
Oklin value was 0.9, exceeding the recommended
value of 0.6 and Bartlett’s Test of Sphericity reached
statistical significance (<0.001), supporting the
factorability of the correlation matrix.
PCA revealed the presence of three components. To
aid on interpretation of these components, several
rotation techniques revealed the presence of a simple
structure with three components. Most of the items
loading substantially on component 1 describing the
general impact of fatigue (general fatigue
component), items describing the impact on
energetic and functional status loaded on component
2 (functional ability component), and itemse 2 Pattern and Structure Matrix for PCA with Oblimin Rotati
ing values ≤ 0.3 were not demonstrated)
s
Component 1
Pattern Structure
el weak all over 0.94 0.89
el fatigued 0.83 0.86
el listless 0.77 0.84
ve trouble starting things 0.53 0.82
ve trouble finishing things 0.44 0.77
ve energy 0.43
able to do my usual activities 0.27
frustrated by being too tired 0.62
ve to limit my social activity 0.61describing the psychosocial impact of fatigue loaded
on component 3 (psychosocial component) as shown
in Table 2.
The correlations between total score and each
dimension were ≥ 0.64 and within dimensions ≥0.43
(p < 0.001 for all; Additional file 1: Table S2 ). There
was a high correlation between the total score of the
13-item FACIT-F and the 9-item short version
(r = 0.99; p < 0.001), indicating no loss of
information after removing four items.3) Rasch analysis
Initial inspection of the fit of data from the 9-item
FACIT-F to the Rasch model showed a significant
item–trait interaction with a total chi-square 308.2
with 81 degrees of freedom, p < 0.00001, suggesting
some degree of misfit between the data and the
model. This misfit to the model expectations may be
due to items or respondents or both. The residual
mean value for items was −0.517 with (a SD of 4.39,
indicating inadequate fit to the model. The fit of the
individual items was checked revealing misfit of
several items to the model expectation. Most items
showed fit residual values above ± 2.5 indicating
significant deviation from the model. Rasch analysis
was applied using an iterative process to achieve the
best possible fit. Finally, the analysis of the pattern of
residuals provided a reasonable explanation when the
residuals loaded on mainly three subscales
(components) with eigen value >1. This step showed
significant improvement in fitting the Rasch model
where items of each of the three components had
residuals within the acceptable range of ±2.5. This
finding was also supported by the t-test of local
independence assumption further supporting that the
FACIT-F is not a unidimensional construct in COPD.
(Detailed description can be seen in Additional file 3).on of three factors solution of the 9-item FACIT scale
Components
Component 2 Component 3
Pattern Structure Pattern Structure
0.30 0.56
0.30 0.60
0.35 0.61
0.37 0.43 0.79
0.33 0.50 0.79
0.91 0.88 0.36
0.85 0.9 0.36
0.38 0.90 0.91
0.40 0.90 0.91
Table 3 Correlations between total and dimensional
scores of FACIT Fatigue Scale and SGRQ and mMRC
dyspnoea scale
Total
SGRQ
score
SGRQ
Symptom
score
SGRQ
Activity
score
SGRQ
Impact
score
mMRC
dyspnoea
scale
score
Total fatigue score
of 13-items
FACIT-F scale)
- 0.7 - 0.45 - 0.58 - 0.7 - 0.48
Total fatigue score
of 9-items modified
FACIT-F
- 0.69 - 0.44 - 0.58 - 0.69 - 0.47
Modified FACIT-F:
General dimension
- 0.65 - 0.44 - 0.52 - 0.65 - 0.44
Modified FACIT-F:
Functional Ability
dimension
- 0.42 - 0.25 - 0.38 - 0.41 - 0.31
Modified FACIT-F:
Psychosocial
dimension
- 0.63 - 0.37 - 0.53 - 0.62 - 0.44
All presented correlations have p <0.001.
mMRC dyspnoea scale: The modified Medical Research Council dyspnoea
scale; SGRQ: St. George’s Respiratory Questionnaire.
Table 4 FACIT-fatigue scores in COPD groups defined
according to CES-D scores and 6MWD, mean values and
standard deviations are shown
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−0.49 with a SD of 1.36 indicating no significant
misfit among the respondents in the sample.
Individual person fit statistics showed that only 42
respondents had residuals outside the acceptable
range. On removal of these persons, the chi squared
interaction statistic did not change significantly
with the PSI remaining high at 0.88 indicating the
scale can constructively differentiate between
groups. Further, when excluding patients with
missing items (n = 24), the Cronbach α of the
FACIT-F was 0.91.
None of the 9 items had disordered threshold
indicating that response options were correctly
ordered - the probability of endorsing more severe
options increases in a logical progression. There was
no sign of differential item functioning (DIF)
indicating that the 9-item FACIT-F was not biased
by the type of the responder (for example by the
subjects’ gender).
For accuracy and comparative validity a
backward-forward revising step was performed;
i.e., the Rasch analysis was separately run on the
13-item FACIT-F which showed that two of the
deleted items “I need to sleep during the day”
and “I am too tired to eat” had disordered
threshold and reordering their scoring system did
not improve the fitness of the FACIT-F to the Rasch
model. We also observed that the three deleted
items “I need to sleep during the day”, “I am too
tired to eat” and “I need help to do my usual
activities” appeared unusual in the context of
fatigue in COPD by having independently the
strongest loading on
three separate components (Detailed description
can be seen in Additional file 4).Depression 6MWD
4) Reliability and Validity of the modified FACIT-F
instrumentNot
depressed
Depressed ≥350 m <350 m
Total fatigue score
of 13-items
FACIT-F scale)
38.5 (8.9) 25.6 (9.6) 38.1 (9.5) 31.1 (10.8)
Total fatigue score
of 9-items modified
FACIT-F
25.5 (6.9) 15.6 (9.6) 25.3 (7.2) 20.1 (8.2)
Modified FACIT-F:
General dimension
15 (4.2) 9.4 (4.6) 14.7 (4.4) 12 (5.1)
Modified FACIT-F:
Functional Ability
dimension
4.4 (1.9) 3.1 (1.6) 4.4 (1.9) 3.6 (1.8)
Modified FACIT-F:
Psychosocial
dimension
6.1 (2.2) 3.5 (2.4) 6.1 (2.2) 4.5 (2.6)
All presented values have a p value <0.001.
CES-D: the Centre for Epidemiologic Studies Depression scale; 6MWD:
6-Minute Walk Distance measured in meters.Reliability of FACIT-F scale:
Using Cronbach’s α for measuring internal
consistency for the 9-item modified scale and each
dimension we found values of 0.91, 0.91, 0.73 and
0.86 respectively at baseline, and values of 0.90, 0.87,
0.69 and 0.87 respectively at 3 years follow up. For
the original 13-item scale, Cronbach’s α at baseline
and at 3 years follow up were 0.92 and 0.93.
Validity of FACIT scale:
The original scale and the modified version and its
dimensions showed good convergent validity
achieving highly significant correlation with SGRQ
and mMRC dyspnoea scale (Table 3).
Patients with high depression scores and exercise
intolerance reported significantly more fatigue than
patients with low depression scores and exercisetolerant patients (Table 4), as also demonstrated
using the Receiver Operating Characteristic (ROC)
curve (in the Additional file 1).Discussion
This study presents a novel simple 9-item modified ver-
sion of the FACIT-F scale to measure fatigue in COPD.
The modified FACIT-F had a high level of convergent
validity supported by significant correlations with widely
used robust scales in COPD such as SGRQ and mMRC
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validity between patients with depressive symptoms or
limited exercise capacity versus patients who did not. In
addition to the overall assessment of fatigue, the scale
offers a novel assessment of multiple fatigue underlying
components in COPD patients.
In this study, we explored the structure of the scale
using a classic analysis framework followed by a PCA
and Rasch analysis. Our analysis indicated that 4 items
were likely suitable for deletion either due to lack of ap-
plicability or redundancy. Indeed, item “I feel tired” had
a high correlation with 2 other items (items 1 and 5)
particularly with item “I feel fatigued”; and the vast ma-
jority of our sample reported that certain items “I am
too tired to eat” and “I need help to do my usual activ-
ities” were less likely to be relevant to fatigue in COPD.
This loss of relevance may be due to a specific disease
representation. For instance, fatigue can be significantly
associated with certain symptoms such as loss of appe-
tite in cancer [26] and neuromuscular dysfunction in
multiple sclerosis [4]. Normal tiredness is usually
resolved by sleep; however, pathogenic fatigue seems less
responsive to sleep [16,27]. This may explain the low r2
coefficient, 0.29, of item “I need to sleep during the day”
as patients with COPD commonly suffer from disturbed
and poor quality of sleep [28].
There are a number of consistent statistical indicators
of the validity of deleting the aforementioned items.
First, the modified 9-item FACIT-F maintained the same
level of correlation with the well-established robust
scales validated in COPD including SGRQ and mMRC
dyspnoea and was able to detect patients with severe
COPD, high depressive symptoms or poor exercise per-
formance. Secondly, a Cronbach’s α of > 0.7 indicates a
good internal consistency. A shorter scale would be gen-
erally expected to have lower level of Cronbach’s α [24];
however, the 9-item modified FACIT-F maintained the
high level of internal consistency of 0.91, similar to the
original 13-item FACIT-F confirming the reliability of
the scale after removal of the four items. Thirdly,
PCA showed that all the 9 items loaded with no less
than 0.4 on their components. This suggested that the
retained items are able to capture descriptives of fatigue
in COPD. Moreover, fatigue in COPD is likely a multi-
dimensional phenomenon [16,29], and the dimensional-
ity of the FACIT-F scale might reflect fundamental
domains of fatigue in COPD.
The deletion of items was further supported by the
Rasch analysis. This advanced technique showed that
none of the items had disordered threshold or significant
bias. Interestingly, the good person residual value sug-
gested that the respondents were likely in a position of
ease to understand and respond to the items. This was
also observed by a high level of completeness where> 96% of the patients completed the questionnaire at both
the visits without omitting items. The Rasch analysis also
showed that the items in the original or modified FACIT-F
did not form a unidimensional structure. This indicates
that fatigue in COPD is more likely a multi-dimensional
phenomenon [16], particularly in that both the modified
FACIT-F and its components correlated well with robust
scales such as SGRQ, mMRC dyspnoea and 6MWT. These
underlying components seemed able to detect further fea-
tures of fatigue in COPD. For instance, the psychosocial
dimension of the modified FACIT-F was more sensitive
(than the other dimensions) in differentiating between
depressed and not depressed where the not depressed
group scored almost double (indicating less fatigued) than
the depressed as shown in Table 4. This suggests that the
scale would offer an overall assessment of fatigue; and be-
sides its underlying components could also provide fur-
ther exploratory assessment for specific patterns of fatigue
in COPD.
Other multi-dimensional scales have been used in
assessing fatigue in COPD such as the 27-item Man-
chester COPD fatigue scale (MCFS) [16,30], the 20-item
Multidimensional Fatigue Index (MFI-20) [31], the 41
visual analogue Piper Fatigue Scale (PFS) [32] and the 40
item Fatigue Impact Scale (FIS) [33]. None of these rela-
tively long scales were developed as disease-specific
scales except for the MCFS. The FACIT-F has shown
significant correlation with MCFS (r = −0.81, p < 0.001),
although the more comprehensive MCFS had shown
better correlation with SGRQ, 6-MWD and BODE index
[16]. However, generally, a shorter valid scale like the 9-
item modified FACIT-F would have the advantages of
ease of administration, would be less time consuming
and probably have a better level of completeness, par-
ticularly when included in a battery of self-reported
questionnaires administered to subjects at the same trial
visit or when used in a busy clinic in daily practice.
Having a short questionnaire that retains excellent re-
liability for the assessment of fatigue has several advan-
tages. In COPD, there has so far been a discrepancy
between the few, and often non-validated, assessment
questions used in the clinical management of COPD
patients and the increasing number of questionnaires
applied in observational studies as well as clinical trials.
The exception has been the MRC dyspnoea scale [12]
but this is a uni-dimensional scale capturing a single as-
pect of COPD – activity limitation. The recent work on
the COPD Assessment Test (CAT) has resulted in a tool
providing a standardised assessment of several respira-
tory symptoms likely to be used in both the clinical set-
ting and in studies [34,35]. However, the CAT does not
capture relevant aspects of fatigue. We suggest that the
short fatigue scale resented in here will improve the as-
sessment of this important aspect in COPD.
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ondary analysis of an existing scale and the items of the
COPD-version FACIT-F have not been generated by
COPD patients. However, in a previous study FACIT-F
had correlated well with a robust COPD specific fatigue
scale (the 27 items Manchester COPD Fatigue Scale)
[16], and here both original and modified FACIT-F
demonstrated strong linear and binary correlation with
well-established measures in COPD such as SGRQ,
mMRC dyspnoea and 6MWT supporting its still validity
in COPD field. Secondly, we did not report data on the
test-retest repeatability and we did not measure the sen-
sitivity of FACIT-F after a medical intervention such as
pulmonary rehabilitation. However, the scale maintained
the same excellent level of internal consistency at base-
line and at 3 years follow up, and demonstrated good
correlation with other robust scales. Therefore, we
would expect the FACIT-F COPD-version to respond to
interventions such as pulmonary rehabilitation, particu-
larly since studies have recently indicated an improve-
ment in fatigue following pulmonary rehabilitation [6].
However, more studies are required to study fatigue
descriptors and influence and its response both totally
and dimensionally after medical intervention using more
sophisticated tools.
In conclusion, we found that both the original and the
modified version of the FACIT-F were reliable and valid
scales offering efficient measurement of fatigue in
COPD. The modified version is shorter, offering total
and dimensional fatigue assessment and is easier to
complete in a busy daily practice and when included in a
battery of scales in studies.
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